BioSpace News Archive

Deals

Elicio Therapeutics Announces $7.0 Million Private Placement Financing

Elicio Therapeutics, Inc. announced today that it has entered into a subscription agreement to sell 1,213,000 shares of its common stock at a purchase price of $5.81 per share in a private placement to GKCC, LLC.

December 22, 2023
·
4 min read
Business

Catheter Precision, Inc. Reports Third Quarter Results of Operations and Filing of Third Quarter 10-Q

Catheter Precision, Inc. announced corporate highlights of the third quarter of 2023.

December 22, 2023
·
8 min read
Drug Development

Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300

Tyra Biosciences, Inc. today announced that it has initiated the SURF201 Phase 1 study of TYRA-200 and provided positive updates on its oral FGFR3-selective inhibitor, TYRA-300.

December 22, 2023
·
8 min read
Drug Development

First patient dosed in Clarity’s registrational Phase III prostate cancer trial with Cu-64 SAR-bisPSMA

Clarity Pharmaceuticals is pleased to announce that the first patient has been dosed in its pivotal Phase III 64Cu-SAR-bisPSMA diagnostic trial in prostate cancer, CLARIFY (NCT06056830)1, at the Urology Cancer Center / XCancer Omaha, NE.

December 22, 2023
·
6 min read
Drug Development

Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the first participant has been dosed in ORION, a randomized, double-blind, placebo-controlled Phase 3 clinical trial of AMX0035.

December 22, 2023
·
7 min read
Deals

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

Cyclacel Pharmaceuticals, Inc. announced today that it has entered into a definitive agreement for the purchase and sale of 388,200 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.315 per share of common stock.

December 22, 2023
·
6 min read
Pharm Country

Feinstein Institutes Leader Calls for a Federally-Funded, National Maternal Health Moonshot

The United States has the highest maternal mortality rate among developed nations – with worse health outcomes for Black women and other minority groups.

December 22, 2023
·
4 min read
IRLAB Increases its Liquidity with a Loan Facility of Up to SEK 55 Million that Extends Financial Runway and Increases Business Opportunities

IRLAB Therapeutics, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company has entered into a loan agreement of up to SEK 55 million issued by Formue Nord Fokus A/S.

December 22, 2023
·
3 min read
Policy

FDA Roundup: December 22, 2023

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

December 22, 2023
·
5 min read
Pharm Country

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - December 22, 2023

Madrigal Pharmaceuticals, Inc. announced that the company granted equity awards to thirty-two new employees with a grant date of December 19, 2023 as equity inducement awards outside of the Company’s Amended 2015 Stock Plan under the terms of the company’s 2023 Inducement Plan.

December 22, 2023
·
1 min read